Low-coverage, genome-wide sequencing of cell-free DNA developed for noninvasive prenatal testing (NIPT) to enable genomic characterization that can be used to monitor immunotherapy response in cancer patients.

Taylor J. Jensen,Aaron Goodman,Shumei Kato,Christopher K. Ellison,Gregory A. Daniels,Lisa Tran,Erin McCarthy,Prachi Nakashe,Amin R. Mazloom,Graham McLennan,Daniel S. Grosu,Mathias Ehrich,Razelle Kurzrock

Low-coverage, genome-wide sequencing of cell-free DNA developed for noninvasive prenatal testing (NIPT) to enable genomic characterization that can be used to monitor immunotherapy response in cancer patients.

2018

Taylor J. Jensen
Aaron Goodman
Shumei Kato
Christopher K. Ellison
Gregory A. Daniels
Lisa Tran
Erin McCarthy
Prachi Nakashe
Amin R. Mazloom
Graham McLennan
Daniel S. Grosu
Mathias Ehrich
Razelle Kurzrock

e24050Background: DNA harboring tumor-specific mutations has been detected in the blood of cancer patients and may be a representative surrogate of the primary tumor and metastases. While most liqu...

Keywords:

Cell-free fetal DNA
Cancer
Genome
Immunotherapy
Pathology
Medicine
Cancer research
Primary tumor
DNA

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations